Study for the effect on blood glucose fluctuation by switching from DPP-4 inhibitor to SGLT2 inhibitor or to DPP-4 inhibitor/SGLT2 inhibitor combination tablet in patients with type 2 diabetes. - multicenter, prospective, randomized, open-label, parallel group, comparison study

Phase 4

• Conditions: type 2 diabetes mellitus

• Registration Number: JPRN-UMIN000029628
• Lead Sponsor: Hokkaido University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-10-19
• Study Completion: 2019-03-22
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 101

Inclusion Criteria

Not provided

Exclusion Criteria

1) hypersensitivity to canagliflozin or teneligliptin/ canagliflozin combination tablet. 2) uncontrolled diabetic retinopathy 3) severe liver dysfunction, renal dysfunction, or heart failure 4) pregnancy, nursing woman or possibly pregnant woman 5) severe diabetic ketosis, diabetic coma 6) severe infection, pre and post operation , severe trauma 7) uncontrolled diet therapy 8) deficiency of insulin secretion 9) BMI < 22kg/m2 10) eGFR < 45ml/min 11) patients who thought to be inappropriate to enter this study for some reasons by physician's judgments

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mean amplitude of glycemic excursions during meal tolerance test

Secondary Outcome Measures

Name	Time	Method
CGM measurements (M-value, SD, average daily risk range, AUC of blood glucose, MODD, average glucose level during meal tolerance test) Weight Blood pressure